SK-GT-4 Cells

The SK-GT-4 cell line is a human esophageal adenocarcinoma model derived from primary adenocarcinoma arising in dysplastic Barrett’s metaplasia of the distal esophagus. This cell line is part of the SK-GT series established at the Memorial Sloan-Kettering Cancer Center and has been instrumental in studying the progression of Barrett’s esophagus to esophageal adenocarcinoma. SK-GT-4 cells exhibit epithelial characteristics and serve as a valuable tool for investigating molecular mechanisms of esophageal cancer, particularly those involving p53 tumor suppressor gene mutations.

Genomic studies of SK-GT-4 have identified a mutation in the TP53 gene, specifically a G to A transition at codon 175 in exon 5, resulting in an arginine-to-histidine substitution. This mutation has been correlated with chemoresistance to DNA-damaging agents such as 5-fluorouracil, mitomycin C, and cisplatin. Studies indicate that the mutational status of p53 significantly impacts the cellular response to chemotherapy, influencing cell cycle regulation and apoptosis in SK-GT-4 cells. These features make this cell line a critical model for exploring therapeutic strategies targeting p53-associated pathways.

SK-GT-4 has been utilized to evaluate tumor invasion potential and response to growth factors in esophageal adenocarcinoma. This cell line has demonstrated invasive capabilities in Boyden chamber assays, highlighting its relevance for studying metastasis. SK-GT-4 also expresses transcripts for various growth factors, including TGF-β and platelet-derived growth factor, which contribute to its aggressive phenotype. The cell line’s established role in translational research underscores its utility in both basic cancer biology and drug development.